aZhongshan Ophthalmic Center, Sun Yat-sen University, WHO Collaborating Centre for Eye Care and Vision, State Key Laboratory of Ophthalmology, Guangdong Provincial Key Laboratory of Ophthalmology and ...

March 20 (Reuters) - EyePoint (EYPT.O), opens new tab filed a lawsuit on Friday accusing rival Ocular Therapeutix (OCUL.O), opens new tab of spreading false or misleading information about EyePoint ...

I’ve had the great thrill of seeing the northern lights, both from Alaska and Iceland. But that experience pales next to what I witnessed recently at my favorite coffee shop. I was there for my usual ...

An Ocular Therapeutix drug developed for the wet form of age-related macular degeneration was better at helping patients maintain vision compared to a blockbuster Regeneron Pharmaceuticals drug that ...

Ocular Therapeutix (OCUL) lost ~22% in the premarket on Tuesday after the company released data from a late-stage trial evaluating Axpaxli, its experimental therapy for wet age-related macular ...

Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched position in wet age-related macular degeneration (AMD) with investigational ...

Axpaxli shows modest advantage over Eylea in trial Retinal specialists may value trial data more than investors, analyst says Ocular plans FDA discussions and marketing application The ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Plotting a challenge to Regeneron’s blockbuster Eylea, Ocular Therapeutix has hired “a key architect” of its rival’s launch to head its commercial team. David Robinson has joined Ocular as global ...